{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T10:27:10Z","timestamp":1781951230542,"version":"3.54.5"},"reference-count":108,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCR"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Even before its role in platelet inhibition was fully characterized in the 1980s, aspirin\nhad been incorporated into the cardiovascular disease care algorithm. Early trials examining its use in\nunstable angina and acute myocardial infarction revealed evidence of its protective role in the secondary\nprevention of atherosclerotic cardiovascular disease (ASCVD). Large trials assessing use in the\nprimary prevention setting and optimal dosing regimens were studied in the late 1990s and early\n2000s. As a cornerstone of cardiovascular care, aspirin was incorporated into primary and secondary\nASCVD prevention guidelines in the United States and mechanical heart valve guidelines. However,\nin recent years, with significant advances in medical and interventional ASCVD therapies, scrutiny\nhas been placed on the bleeding profile of aspirin, and guidelines have adapted to new evidence. Updates\nin primary prevention guidelines reserve aspirin only for patients at higher ASCVD risk and low\nbleeding risk - though questions remain in ASCVD risk assessment as risk-enhancing factors have\nproven difficult to incorporate on a population level. New thoughts regarding aspirin use in secondary\nprevention - especially with the concomitant use of anticoagulants - have altered recommendations as\nadditional data accrued. Finally, a recommendation for aspirin and vitamin K antagonists with mechanical\nheart valves has been modified. Despite aspirin losing a foothold in cardiovascular care, new\nevidence has strengthened claims for its use in women at high risk for preeclampsia.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573403x19666230502163828","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T06:25:12Z","timestamp":1683095112000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Redefining the Roles of Aspirin across the Spectrum of Cardiovascular\nDisease Prevention"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-0478","authenticated-orcid":true,"given":"Matthew T.","family":"Brown","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina S.","family":"Bortfeld","sequence":"additional","affiliation":[{"name":"Department\nof Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence S.","family":"Sperling","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0990-6151","authenticated-orcid":true,"given":"Nanette K.","family":"Wenger","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1161\/CIR.0000000000000677","volume":"140","author":"Arnett D.K.","year":"2019","unstructured":"Arnett D.K.; Blumenthal R.S.; Albert M.A.; 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: Executive summary: A report of the American college of cardiology\/American heart association task force on clinical practice guidelines. Circulation 2019,140(11),e563-e595","journal-title":"Circulation"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc21-S010","volume":"44","year":"2021","unstructured":"American Diabetes Association 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes\u20142021. Diabetes Care 2021,44(Suppl. 1),S125-S150","journal-title":"Diabetes Care"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1001\/jama.2022.4983","volume":"327","author":"Davidson K.W.","year":"2022","unstructured":"Davidson K.W.; Barry M.J.; Mangione C.M.; Aspirin use to prevent cardiovascular disease. JAMA 2022,327(16),1577-1584","journal-title":"JAMA"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/S0140-6736(20)30315-9","volume":"395","author":"Chiarito M.","year":"2020","unstructured":"Chiarito M.; Sanz-S\u00e1nchez J.; Cannata F.; Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet 2020,395(10235),1487-1495","journal-title":"Lancet"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","volume":"397","author":"Koo B.K.","year":"2021","unstructured":"Koo B.K.; Kang J.; Park K.W.; Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): An investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet 2021,397(10293),2487-2496","journal-title":"Lancet"},{"key":"ref=6","first-page":"CD003464","volume":"2013","author":"Massel D.R.","year":"2013","unstructured":"Massel D.R.; Little S.H.; Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev 2013,2013(7),CD003464","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=7","first-page":"e72","volume":"143","author":"Otto C.M.","year":"2021","unstructured":"Otto C.M.; Nishimura R.A.; Bonow R.O.; 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021,143(5),e72-e227","journal-title":"Circulation"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1001\/jama.2021.14781","volume":"326","author":"Davidson K.W.","year":"2021","unstructured":"Davidson K.W.; Barry M.J.; Mangione C.M.; Aspirin use to prevent preeclampsia and related morbidity and mortality. JAMA 2021,326(12),1186-1191","journal-title":"JAMA"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","volume":"63","author":"Goff D.C.","year":"2014","unstructured":"Goff D.C.; Lloyd-Jones D.M.; Bennett G.; 2013 ACC\/AHA guideline on the assessment of cardiovascular risk. J Am Coll Cardiol 2014,63(25)(25 Pt B),2935-2959","journal-title":"J Am Coll Cardiol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1016\/j.jacc.2019.03.501","volume":"73","author":"Abdelaziz H.K.","year":"2019","unstructured":"Abdelaziz H.K.; Saad M.; Pothineni N.V.K.; Aspirin for primary prevention of cardiovascular events. J Am Coll Cardiol 2019,73(23),2915-2929","journal-title":"J Am Coll Cardiol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.amjcard.2019.08.040","volume":"124","author":"Thobani A.","year":"2019","unstructured":"Thobani A.; Dhindsa D.S.; DeMoss B.D.; Usefulness of aspirin for primary prevention of atherosclerotic cardiovascular disease. Am J Cardiol 2019,124(11),1785-1789","journal-title":"Am J Cardiol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/clc.23218","volume":"42","author":"Wenger N.K.","year":"2019","unstructured":"Wenger N.K.; Female-friendly focus: 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease. Clin Cardiol 2019,42(8),706-709","journal-title":"Clin Cardiol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"Visseren F.L.J.","year":"2021","unstructured":"Visseren F.L.J.; Mach F.; Smulders Y.M.; 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021,42(34),3227-3337","journal-title":"Eur Heart J"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJM198907203210301","volume":"321","year":"1989","unstructured":"Steering Committee of the Physicians\u2019 Health Study Research Group Final report on the aspirin component of the ongoing Physicians\u2019 Health Study. N Engl J Med 1989,321(3),129-135","journal-title":"N Engl J Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa050613","volume":"352","author":"Ridker P.M.","year":"2005","unstructured":"Ridker P.M.; Cook N.R.; Lee I.M.; A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005,352(13),1293-1304","journal-title":"N Engl J Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","volume":"296","author":"Peto R.","year":"1988","unstructured":"Peto R.; Gray R.; Collins R.; Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988,296(6618),313-316","journal-title":"BMJ"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","volume":"351","year":"1998","unstructured":"The Medical Research Council\u2019s General Practice Research Framework Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998,351(9098),233-241","journal-title":"Lancet"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","volume":"357","author":"Roncaglioni M.C.","year":"2001","unstructured":"Roncaglioni M.C.; Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general Practice. Lancet 2001,357(9250),89-95","journal-title":"Lancet"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","volume":"392","author":"Gaziano J.M.","year":"2018","unstructured":"Gaziano J.M.; Brotons C.; Coppolecchia R.; Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): A randomised, double-blind, placebo-controlled trial. Lancet 2018,392(10152),1036-1046","journal-title":"Lancet"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","volume":"379","author":"Bowman L.","year":"2018","unstructured":"Bowman L.; Mafham M.; Wallendszus K.; Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018,379(16),1529-1539","journal-title":"N Engl J Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","volume":"379","author":"McNeil J.J.","year":"2018","unstructured":"McNeil J.J.; Nelson M.R.; Woods R.L.; Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med 2018,379(16),1519-1528","journal-title":"N Engl J Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","volume":"379","author":"McNeil J.J.","year":"2018","unstructured":"McNeil J.J.; Wolfe R.; Woods R.L.; Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 2018,379(16),1509-1518","journal-title":"N Engl J Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"396","DOI":"10.7326\/0003-4819-150-6-200903170-00008","volume":"150","author":"Force U.S.P.S.T.","year":"2009","unstructured":"Force U.S.P.S.T.; Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009,150(6),396-404","journal-title":"Ann Intern Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1001\/jama.2022.3337","volume":"327","author":"Guirguis-Blake J.M.","year":"2022","unstructured":"Guirguis-Blake J.M.; Evans C.V.; Perdue L.A.; Bean S.I.; Senger C.A.; Aspirin use to prevent cardiovascular disease and colorectal cancer. JAMA 2022,327(16),1585-1597","journal-title":"JAMA"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"a1840","DOI":"10.1136\/bmj.a1840","volume":"337","author":"Belch J","year":"2008","unstructured":"Belch J; MacCuish A; Campbell I; The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ 2008,337((oct16 2)),a1840","journal-title":"BMJ"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1001\/jama.2008.623","volume":"300","author":"Ogawa H.","year":"2008","unstructured":"Ogawa H.; Nakayama M.; Morimoto T.; Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial. JAMA 2008,300(18),2134-2141","journal-title":"JAMA"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jama.2010.221","volume":"303","author":"Fowkes F.G.","year":"2010","unstructured":"Fowkes F.G.; Price J.F.; Stewart M.C.; Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: A randomized controlled trial. JAMA 2010,303(9),841-848","journal-title":"JAMA"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1001\/jama.2014.15690","volume":"312","author":"Ikeda Y.","year":"2014","unstructured":"Ikeda Y.; Shimada K.; Teramoto T.; Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: A randomized clinical trial. JAMA 2014,312(23),2510-2520","journal-title":"JAMA"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","volume":"203","author":"Chasman D.I.","year":"2009","unstructured":"Chasman D.I.; Shiffman D.; Zee R.Y.L.; Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 2009,203(2),371-376","journal-title":"Atherosclerosis"},{"key":"ref=30","first-page":"1","volume":"6","author":"Trinder M.","year":"2020","unstructured":"Trinder M.; Uddin M.M.; Finneran P.; Aragam K.G.; Natarajan P.; Clinical utility of lipoprotein(a) and LPA genetic risk score in risk prediction of incident atherosclerotic cardiovascular disease. JAMA Cardiol 2020,6(3),1-9","journal-title":"JAMA Cardiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","volume":"80","author":"Lacaze P.","year":"2022","unstructured":"Lacaze P.; Bakshi A.; Riaz M.; Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes. J Am Coll Cardiol 2022,80(14),1287-1298","journal-title":"J Am Coll Cardiol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"Hansson L.","year":"1998","unstructured":"Hansson L.; Zanchetti A.; Carruthers S.G.; Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998,351(9118),1755-1762","journal-title":"Lancet"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1001\/jama.2022.3385","volume":"327","author":"Dehmer S.P.","year":"2022","unstructured":"Dehmer S.P.; O\u2019Keefe L.R.; Evans C.V.; Guirguis-Blake J.M.; Perdue L.A.; Maciosek M.V.; Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Modeling Study for the US Preventive Services Task Force. JAMA 2022,327(16),1598-1607","journal-title":"JAMA"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/bjh.14520","volume":"177","author":"Desborough M.J.R.","year":"2017","unstructured":"Desborough M.J.R.; Keeling D.M.; The aspirin story-From willow to wonder drug. Br J Haematol 2017,177(5),674-683","journal-title":"Br J Haematol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1056\/NEJM198308183090703","volume":"309","author":"Lewis H.D.","year":"1983","unstructured":"Lewis H.D.; Davis J.W.; Archibald D.G.; Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983,309(7),396-403","journal-title":"N Engl J Med"},{"key":"ref=36","first-page":"349","volume":"2","year":"1988","unstructured":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988,2(8607),349-360","journal-title":"Lancet"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","volume":"308","year":"1994","unstructured":"Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists\u2019 Collaboration. BMJ 1994,308(6921),81-106","journal-title":"BMJ"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Collaboration A.T.","year":"2002","unstructured":"Collaboration A.T.; Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002,324(7329),71-86","journal-title":"BMJ"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/S0735-1097(01)01682-5","volume":"38","author":"Smith S.C.","year":"2001","unstructured":"Smith S.C.; Blair S.N.; Bonow R.O.; AHA\/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. J Am Coll Cardiol 2001,38(5),1581-1583","journal-title":"J Am Coll Cardiol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","volume":"113","author":"Smith S.C.","year":"2006","unstructured":"Smith S.C.; Allen J.; Blair S.N.; AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006,113(19),2363-2372","journal-title":"Circulation"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","volume":"124","author":"Smith S.C.","year":"2011","unstructured":"Smith S.C.; Benjamin E.J.; Bonow R.O.; AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update. Circulation 2011,124(22),2458-2473","journal-title":"Circulation"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","volume":"358","author":"Mehta S.R.","year":"2001","unstructured":"Mehta S.R.; Yusuf S.; Peters R.J.G.; Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001,358(9281),527-533","journal-title":"Lancet"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"Yusuf S.","year":"2001","unstructured":"Yusuf S.; Zhao F.; Mehta S.R.; Chrolavicius S.; Tognoni G.; Fox K.K.; Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001,345(7),494-502","journal-title":"N Engl J Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","volume":"288","author":"Steinhubl S.R.","year":"2002","unstructured":"Steinhubl S.R.; Berger P.B.; Mann J.T.; Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002,288(19),2411-2420","journal-title":"JAMA"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S0140-6736(84)92446-2","volume":"1","author":"Lorenz R.L.","year":"1984","unstructured":"Lorenz R.L.; Schacky C.V.; Weber M.; Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Effects on platelet aggregation and thromboxane formation. Lancet 1984,1(8389),1261-1264","journal-title":"Lancet"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa020798","volume":"347","author":"Mangano D.T.","year":"2002","unstructured":"Mangano D.T.; Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002,347(17),1309-1317","journal-title":"N Engl J Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1056\/NEJM199308193290802","volume":"329","author":"Turpie A.","year":"1993","unstructured":"Turpie A.; Gent M.; Laupacis A.; A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993,329(8),524-529","journal-title":"N Engl J Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","volume":"154","year":"1994","unstructured":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994,154(13),1449-1457","journal-title":"Arch Intern Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(96)03487-3","volume":"348","year":"1996","unstructured":"Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996,348(9028),633-638","journal-title":"Lancet"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"Committee C.S.","year":"1996","unstructured":"Committee C.S.; A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996,348(9038),1329-1339","journal-title":"Lancet"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJM199903253401201","volume":"340","author":"Kearon C.","year":"1999","unstructured":"Kearon C.; Gent M.; Hirsh J.; A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999,340(12),901-907","journal-title":"N Engl J Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","volume":"49","author":"Bhatt D.L.","year":"2007","unstructured":"Bhatt D.L.; Flather M.D.; Hacke W.; Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007,49(19),1982-1988","journal-title":"J Am Coll Cardiol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"Levine G.N.","year":"2016","unstructured":"Levine G.N.; Bates E.R.; Bittl J.A.; 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J Am Coll Cardiol 2016,68(10),1082-1115","journal-title":"J Am Coll Cardiol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1016\/j.jacc.2019.09.038","volume":"74","author":"Chichareon P.","year":"2019","unstructured":"Chichareon P.; Modolo R.; Collet C.; Efficacy and safety of stents in ST-segment elevation myocardial infarction. J Am Coll Cardiol 2019,74(21),2572-2584","journal-title":"J Am Coll Cardiol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.jacc.2019.11.058","volume":"75","author":"Madhavan M.V.","year":"2020","unstructured":"Madhavan M.V.; Kirtane A.J.; Redfors B.; Stent-related adverse events >1 year after percutaneous coronary intervention. J Am Coll Cardiol 2020,75(6),590-604","journal-title":"J Am Coll Cardiol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/eurheartj\/ehy396","volume":"39","author":"Lip G.Y.H.","year":"2018","unstructured":"Lip G.Y.H.; Collet J.P.; Haude M.; Huber K.; Management of antithrombotic therapy in AF patients presenting with ACS and\/or undergoing PCI. Eur Heart J 2018,39(31),2847-2850","journal-title":"Eur Heart J"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","volume":"381","author":"Dewilde W.J.M.","year":"2013","unstructured":"Dewilde W.J.M.; Oirbans T.; Verheugt F.W.A.; Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 2013,381(9872),1107-1115","journal-title":"Lancet"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","volume":"65","author":"Fiedler K.A.","year":"2015","unstructured":"Fiedler K.A.; Maeng M.; Mehilli J.; Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation. J Am Coll Cardiol 2015,65(16),1619-1629","journal-title":"J Am Coll Cardiol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"Gibson C.M.","year":"2016","unstructured":"Gibson C.M.; Mehran R.; Bode C.; Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016,375(25),2423-2434","journal-title":"N Engl J Med"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"Cannon C.P.","year":"2017","unstructured":"Cannon C.P.; Bhatt D.L.; Oldgren J.; Dual antithrombotic therapy with dabigatran after pci in atrial fibrillation. N Engl J Med 2017,377(16),1513-1524","journal-title":"N Engl J Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"Kirchhof P.","year":"2016","unstructured":"Kirchhof P.; Benussi S.; Kotecha D.; 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016,37(38),2893-2962","journal-title":"Eur Heart J"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli M.","year":"2018","unstructured":"Valgimigli M.; Bueno H.; Byrne R.A.; 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 2018,39(3),213-260","journal-title":"Eur Heart J"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","volume":"138","author":"Angiolillo D.J.","year":"2018","unstructured":"Angiolillo D.J.; Goodman S.G.; Bhatt D.L.; Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Circulation 2018,138(5),527-536","journal-title":"Circulation"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","volume":"143","author":"Angiolillo D.J.","year":"2021","unstructured":"Angiolillo D.J.; Bhatt D.L.; Cannon C.P.; Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: A North American perspective: 2021 update. Circulation 2021,143(6),583-596","journal-title":"Circulation"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1161\/CIRCULATIONAHA.120.046251","volume":"142","author":"O\u2019Donoghue M.L.","year":"2020","unstructured":"O\u2019Donoghue M.L.; Murphy S.A.; Sabatine M.S.; The safety and efficacy of aspirin discontinuation on a background of a P2Y 12 inhibitor in patients after percutaneous coronary intervention. Circulation 2020,142(6),538-545","journal-title":"Circulation"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.amjcard.2021.04.014","volume":"151","author":"Knijnik L.","year":"2021","unstructured":"Knijnik L.; Fernandes M.; Rivera M.; Meta-analysis of duration of dual antiplatelet therapy in acute coronary syndrome treated with coronary stenting. Am J Cardiol 2021,151,25-29","journal-title":"Am J Cardiol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/jamacardio.2019.3355","volume":"4","author":"Tomaniak M.","year":"2019","unstructured":"Tomaniak M.; Chichareon P.; Onuma Y.; Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes. JAMA Cardiol 2019,4(11),1092-1101","journal-title":"JAMA Cardiol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1001\/jama.2019.8145","volume":"321","author":"Watanabe H.","year":"2019","unstructured":"Watanabe H.; Domei T.; Morimoto T.; Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI. JAMA 2019,321(24),2414-2427","journal-title":"JAMA"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1001\/jama.2019.8146","volume":"321","author":"Hahn J.Y.","year":"2019","unstructured":"Hahn J.Y.; Song Y.B.; Oh J.H.; Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention. JAMA 2019,321(24),2428-2437","journal-title":"JAMA"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1001\/jama.2020.7580","volume":"323","author":"Kim B.K.","year":"2020","unstructured":"Kim B.K.; Hong S.J.; Cho Y.H.; Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome. JAMA 2020,323(23),2407-2416","journal-title":"JAMA"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1093\/eurheartj\/ehaa670","volume":"41","author":"Baber U.","year":"2020","unstructured":"Baber U.; Dangas G.; Angiolillo D.J.; Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J 2020,41(37),3533-3545","journal-title":"Eur Heart J"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"Collet J.P.","year":"2021","unstructured":"Collet J.P.; Thiele H.; Barbato E.; 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021,42(14),1289-1367","journal-title":"Eur Heart J"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1161\/CIR.0000000000001038","volume":"145","author":"Lawton J.S.","year":"2022","unstructured":"Lawton J.S.; Tamis-Holland J.E.; Bangalore S.; 2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: A report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines. Circulation 2022,145(3),e18-e114","journal-title":"Circulation"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","volume":"384","author":"Jones W.S.","year":"2021","unstructured":"Jones W.S.; Mulder H.; Wruck L.M.; Comparative effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med 2021,384(21),1981-1990","journal-title":"N Engl J Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"aeac019","DOI":"10.1093\/ehjopen\/oeac019","volume":"2","author":"Aggarwal D","year":"2022","unstructured":"Aggarwal D; Bhatia K; Chunawala ZS; P2Y12 inhibitor versus\taspirin monotherapy for secondary prevention of cardiovascular\tevents: Meta-analysis of randomized trials. Eur Heart JOpen 2022,2(2),aeac019","journal-title":"Eur Heart JOpen"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1111\/j.1538-7836.2004.01017.x","volume":"2","author":"Woodward M.","year":"2004","unstructured":"Woodward M.; Lowe G.D.O.; Francis L.M.A.; Rumley A.; Cobbe S.M.; A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: The CADET trial. J Thromb Haemost 2004,2(11),1934-1940","journal-title":"J Thromb Haemost"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"e000703","DOI":"10.1161\/JAHA.112.000703","volume":"1","author":"Pettersen A.\u00c5.R.","year":"2012","unstructured":"Pettersen A.\u00c5.R.; Seljeflot I.; Abdelnoor M.; Arnesen H.; High on-aspirin platelet reactivity and clinical outcome in patients with stable coronary artery disease: Results from ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). J Am Heart Assoc 2012,1(3),e000703","journal-title":"J Am Heart Assoc"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/eb-2013-101512","volume":"19","author":"Gorelick P.B.","year":"2014","unstructured":"Gorelick P.B.; Farooq M.U.; Aspirin plus clopidogrel in acute minor ischaemic stroke or transient ischaemic attack is superior to aspirin alone for stroke risk reduction: CHANCE trial. Evid Based Med 2014,19(2),58","journal-title":"Evid Based Med"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1161\/STROKEAHA.116.014891","volume":"48","author":"Wang Y.","year":"2017","unstructured":"Wang Y.; Minematsu K.; Wong K.S.L.; Ticagrelor in acute stroke or transient ischemic attack in asian patients. Stroke 2017,48(1),167-173","journal-title":"Stroke"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.amjcard.2017.09.022","volume":"121","author":"Agarwal N.","year":"2018","unstructured":"Agarwal N.; Mahmoud A.N.; Patel N.K.; Meta-analysis of aspirin versus dual antiplatelet therapy following coronary artery bypass grafting. Am J Cardiol 2018,121(1),32-40","journal-title":"Am J Cardiol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1093\/eurheartj\/ehz185","volume":"40","author":"Schunkert H.","year":"2019","unstructured":"Schunkert H.; Boening A.; von Scheidt M.; Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial. Eur Heart J 2019,40(29),2432-2440","journal-title":"Eur Heart J"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"e026053","DOI":"10.1136\/bmjopen-2018-026053","volume":"9","author":"Leonardi S.","year":"2019","unstructured":"Leonardi S.; Franzone A.; Piccolo R.; Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY). BMJ Open 2019,9(3),e026053","journal-title":"BMJ Open"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/ejcts\/ezab389","volume":"60","author":"Beyersdorf F.","year":"2021","unstructured":"Beyersdorf F.; Vahanian A.; Milojevic M.; 2021 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg 2021,60(4),727-800","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.amjcard.2011.07.049","volume":"108","author":"Ussia G.P.","year":"2011","unstructured":"Ussia G.P.; Scarabelli M.; Mul\u00e8 M.; Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2011,108(12),1772-1776","journal-title":"Am J Cardiol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.jcin.2017.04.014","volume":"10","author":"Rod\u00e9s-Cabau J.","year":"2017","unstructured":"Rod\u00e9s-Cabau J.; Masson J.B.; Welsh R.C.; Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve. JACC Cardiovasc Interv 2017,10(13),1357-1365","journal-title":"JACC Cardiovasc Interv"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"959","DOI":"10.21037\/jtd.2019.01.87","volume":"11","author":"Zuo W.","year":"2019","unstructured":"Zuo W.; Yang M.; He Y.; Hao C.; Chen L.; Ma G.; Single or dual antiplatelet therapy after transcatheter aortic valve replacement: an updated systemic review and meta-analysis. J Thorac Dis 2019,11(3),959-968","journal-title":"J Thorac Dis"},{"key":"ref=87","first-page":"e201633","volume":"2016","author":"ElGuindy A.","year":"2016","unstructured":"ElGuindy A.; PARTNER 2A and SAPIEN 3: TAVI for intermediate risk patients. Glob Cardiol Sci Pract 2016,2016(4),e201633","journal-title":"Glob Cardiol Sci Pract"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa1911425","volume":"382","author":"Dangas G.D.","year":"2020","unstructured":"Dangas G.D.; Tijssen J.G.P.; W\u00f6hrle J.; A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 2020,382(2),120-129","journal-title":"N Engl J Med"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0140-6736(86)91891-X","volume":"327","author":"Wallenburg H.C.S.","year":"1986","unstructured":"Wallenburg H.C.S.; Makovitz J.W.; Dekker G.A.; Rotmans P.; Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae. Lancet 1986,327(8471),1-3","journal-title":"Lancet"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1056\/NEJM198908103210604","volume":"321","author":"Benigni A.","year":"1989","unstructured":"Benigni A.; Gregorini G.; Frusca T.; Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med 1989,321(6),357-362","journal-title":"N Engl J Med"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJM198908103210603","volume":"321","author":"Schiff E.","year":"1989","unstructured":"Schiff E.; Peleg E.; Goldenberg M.; The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. N Engl J Med 1989,321(6),351-356","journal-title":"N Engl J Med"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/0140-6736(90)91377-M","volume":"335","author":"McParland P.","year":"1990","unstructured":"McParland P.; Pearce J.M.; Chamberlain G.V.P.; Doppler ultrasound and aspirin in recognition and prevention of pregnancy-induced hypertension. Lancet 1990,335(8705),1552-1555","journal-title":"Lancet"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/0002-9378(93)90351-I","volume":"168","author":"Hauth J.C.","year":"1993","unstructured":"Hauth J.C.; Goldenberg R.L.; Parker C.R.; Low-dose aspirin therapy to prevent preeclampsia. Am J Obstet Gynecol 1993,168(4),1083-1093","journal-title":"Am J Obstet Gynecol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1056\/NEJM199310213291701","volume":"329","author":"Sibai B.M.","year":"1993","unstructured":"Sibai B.M.; Caritis S.N.; Thom E.; Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. N Engl J Med 1993,329(17),1213-1218","journal-title":"N Engl J Med"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/j.1471-0528.1993.tb14304.x","volume":"100","author":"Viinikka L.","year":"1993","unstructured":"Viinikka L.; Hartikainen-Sorri A.L.; Lumme R.; Hiilesmaa V.; Ylikorkala O.; Low dose aspirin in hypertensive pregnant women: Effect on pregnancy outcome and prostacyclin-thromboxane balance in mother and newborn. BJOG 1993,100(9),809-815","journal-title":"BJOG"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0140-6736(94)92633-6","volume":"343","year":"1994","unstructured":"CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group CLASP: A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994,343(8898),619-629","journal-title":"Lancet"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1600-0897.1994.tb00842.x","volume":"31","author":"Caspi E.","year":"1994","unstructured":"Caspi E.; Raziel A.; Sherman D.; Arieli S.; Bukovski I.; Weinraub Z.; Prevention of pregnancy-induced hypertension in twins by early administration of low-dose aspirin: a preliminary report. Am J Reprod Immunol 1994,31(1),19-24","journal-title":"Am J Reprod Immunol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/0029-7844(95)00340-1","volume":"87","author":"Morris J.","year":"1996","unstructured":"Morris J.; Fay R.; Ellwood D.; Cook C.; Devonald K.; A randomized controlled trial of aspirin in patients with abnormal uterine artery blood flow. Obstet Gynecol 1996,87(1),74-78","journal-title":"Obstet Gynecol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1161\/01.HYP.30.3.589","volume":"30","author":"Hermida R.C.","year":"1997","unstructured":"Hermida R.C.; Ayala D.E.; Iglesias M.; Time-dependent effects of low-dose aspirin administration on blood pressure in pregnant women. Hypertension 1997,30(3),589-595","journal-title":"Hypertension"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1056\/NEJM199803123381101","volume":"338","author":"Caritis S.","year":"1998","unstructured":"Caritis S.; Sibai B.; Hauth J.; Low-dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med 1998,338(11),701-705","journal-title":"N Engl J Med"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/j.1471-0528.1998.tb10088.x","volume":"105","author":"Rotchell Y.E.","year":"1998","unstructured":"Rotchell Y.E.; Cruickshank J.K.; Phillips Gay M.; Barbados Low Dose Aspirin Study in Pregnancy (BLASP): A randomised trial for the prevention of pre-eclampsia and its complications. BJOG 1998,105(3),286-292","journal-title":"BJOG"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1046\/j.1469-0705.2000.00009.x","volume":"15","author":"Grab D.","year":"2000","unstructured":"Grab D.; Paulus W.E.; Erdmann M.; Effects of low-dose aspirin on uterine and fetal blood flow during pregnancy: results of a randomized, placebo-controlled, double-blind trial. Ultrasound Obstet Gynecol 2000,15(1),19-27","journal-title":"Ultrasound Obstet Gynecol"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1471-0528.2003.t01-1-02097.x","volume":"110","author":"Subtil D.","year":"2003","unstructured":"Subtil D.; Goeusse P.; Puech F.; Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: The Essai R\u00e9gional Aspirine M\u00e8re-Enfant study (Part 1). BJOG 2003,110(5),475-484","journal-title":"BJOG"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/uog.218","volume":"22","author":"Yu C.K.H.","year":"2003","unstructured":"Yu C.K.H.; Papageorghiou A.T.; Parra M.; Palma Dias R.; Nicolaides K.H.; Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks\u2019 gestation. Ultrasound Obstet Gynecol 2003,22(3),233-239","journal-title":"Ultrasound Obstet Gynecol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1471-0528.2012.03493.x","volume":"120","author":"Villa P.M.","year":"2013","unstructured":"Villa P.M.; Kajantie E.; R\u00e4ikk\u00f6nen K.; Aspirin in the prevention of pre-eclampsia in high-risk women: A randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. BJOG 2013,120(1),64-74","journal-title":"BJOG"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/NEJMoa1704559","volume":"377","author":"Rolnik D.L.","year":"2017","unstructured":"Rolnik D.L.; Wright D.; Poon L.C.; Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017,377(7),613-622","journal-title":"N Engl J Med"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/uog.17351","volume":"49","author":"Scazzocchio E.","year":"2017","unstructured":"Scazzocchio E.; Oros D.; Diaz D.; Impact of aspirin on trophoblastic invasion in women with abnormal uterine artery Doppler at 11-14 weeks: A randomized controlled study. Ultrasound Obstet Gynecol 2017,49(4),435-441","journal-title":"Ultrasound Obstet Gynecol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"e022056","DOI":"10.1136\/bmjopen-2018-022056","volume":"8","author":"Mone F.","year":"2018","unstructured":"Mone F.; Mulcahy C.; McParland P.; T rial of feasibility and acceptability of routine low-dose aspirin versusE arly S creening T est indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised controlled trial. BMJ Open 2018,8(7),e022056","journal-title":"BMJ Open"}],"container-title":["Current Cardiology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573403X19666230502163828","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/216449\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573403X19666230502163828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T12:52:54Z","timestamp":1698843174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/216449\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":108,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573403x19666230502163828","relation":{},"ISSN":["1573-403X"],"issn-type":[{"value":"1573-403X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e020523216449"}}